Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,751 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Regulatory
116 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Zoledronic Acid | US FDA | Paget Disease | Treatment of Paget’s disease of bone in men and women | approved | Apr 16, 2007 | openfda |
Data updated 17 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Trastuzumab | 68 | 43 | 25 |
| Erlotinib | 65 | 39 | 26 |
| Crizotinib | 56 | 36 | 20 |
| Afatinib | 38 | 35 | 3 |
| Lapatinib | 26 | 15 | 11 |
| Osimertinib | 24 | 14 | 10 |
| Dactolisib | 19 | 11 | 8 |
| Gefitinib | 19 | 11 | 8 |
| Everolimus | 15 | 13 | 2 |
| Trastuzumab Emtansine | 15 | 6 | 9 |
| Neratinib | 13 | 13 | 0 |
| Olaparib | 13 | 12 | 1 |
| Sorafenib |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 13 |
| 10 |
| 3 |
| Pembrolizumab | 12 | 10 | 2 |
| Vemurafenib | 11 | 11 | 0 |
| Carboplatin | 10 | 9 | 1 |
| Cetuximab | 10 | 9 | 0 |
| Gemcitabine | 10 | 6 | 4 |
| Cisplatin | 9 | 7 | 2 |
| Pictilisib | 9 | 9 | 0 |
| Tepotinib | 9 | 9 | 0 |
| Capmatinib | 8 | 7 | 1 |
| Chemotherapy | 8 | 8 | 0 |
| Sunitinib | 8 | 5 | 2 |
| Larotrectinib | 7 | 7 | 0 |
| Trametinib | 7 | 4 | 3 |
| Bevacizumab | 6 | 5 | 1 |
| Capecitabine | 6 | 5 | 1 |
| Entrectinib | 5 | 4 | 1 |
| Paclitaxel | 5 | 3 | 2 |
| Palbociclib | 5 | 5 | 0 |
| Pazopanib | 5 | 4 | 1 |
| Atezolizumab | 4 | 3 | 1 |
| Cabozantinib | 4 | 4 | 0 |
| Dabrafenib | 4 | 3 | 1 |
| Icotinib | 4 | 3 | 1 |
| Immune Checkpoint Inhibitor | 4 | 3 | 0 |
| MTOR Inhibitor | 4 | 4 | 0 |
| Nivolumab | 4 | 2 | 2 |
| Pertuzumab | 4 | 4 | 0 |
| PI3Ka/Di | 4 | 3 | 1 |
| Ruxolitinib | 4 | 4 | 0 |
| Selumetinib | 4 | 4 | 0 |
| Vandetanib | 4 | 4 | 0 |
| Anti-VEGF Monoclonal Antibody | 3 | 2 | 1 |
| Capivasertib | 3 | 3 | 0 |
| Ceritinib | 3 | 2 | 1 |
| Dasatinib | 3 | 3 | 0 |
| Docetaxel | 3 | 2 | 1 |
| Fluorouracil | 3 | 2 | 1 |
| Futibatinib | 3 | 3 | 0 |
| Infigratinib | 3 | 3 | 0 |
| Pemetrexed | 3 | 2 | 1 |
| PI-103 | 3 | 3 | 0 |
| PI3Kbeta Inhibitor AZD8186 | 3 | 3 | 0 |
| Trastuzumab Deruxtecan | 3 | 3 | 0 |
| Akt Inhibitor MK2206 | 2 | 2 | 0 |
| Alectinib | 2 | 1 | 1 |
| Alisertib | 2 | 2 | 0 |
| ARS-1620 | 2 | 2 | 0 |
| Aumolertinib | 2 | 1 | 1 |
| Dacomitinib | 2 | 2 | 0 |
| Dinaciclib | 2 | 2 | 0 |
| Durvalumab | 2 | 2 | 0 |
| Fulvestrant | 2 | 1 | 1 |
| Imatinib | 2 | 2 | 0 |
| Ipilimumab | 2 | 2 | 0 |
| Irbesartan | 2 | 2 | 0 |
| Lenvatinib | 2 | 1 | 1 |
| Metformin | 2 | 2 | 0 |
| PD173074 | 2 | 2 | 0 |
| PD1 Inhibitor | 2 | 1 | 1 |
| Ramucirumab | 2 | 1 | 1 |
| Sacituzumab Govitecan | 2 | 0 | 2 |
| Temsirolimus | 2 | 2 | 0 |
| Zolbetuximab | 2 | 2 | 0 |
| 2-Deoxy-D-glucose | 1 | 1 | 0 |
| 9F7-F11 | 1 | 1 | 0 |
| A66 | 1 | 1 | 0 |
| Abexinostat | 1 | 1 | 0 |
| Adebrelimab | 1 | 1 | 0 |
| Alpelisib | 1 | 1 | 0 |
| Antigen-specific Cytotoxic T-lymphocyte Therapy | 1 | 1 | 0 |
| Anti-PD1 Monoclonal Antibody | 1 | 1 | 0 |
| Anti-PD-L1 Monoclonal Antibody | 1 | 1 | 0 |
| Anti-PDL1 Therapy | 1 | 1 | 0 |
| Anti-TIM-3 Monoclonal Antibody | 1 | 1 | 0 |
| ATR Inhibitor | 1 | 1 | 0 |
| Bortezomib | 1 | 1 | 0 |
| CAPOX Regimen | 1 | 1 | 0 |
| Carboplatin/Paclitaxel Regimen | 1 | 1 | 0 |
| Carboplatin/Pemetrexed Regimen | 1 | 1 | 0 |
| C-DIM 12 | 1 | 0 | 1 |
| Checkpoint Kinase Inhibitor AZD7762 | 1 | 1 | 0 |
| CTLA-4 Inhibitor | 1 | 1 | 0 |
| Dabrafenib/Trametinib Regimen | 1 | 1 | 0 |
| Dovitinib | 1 | 1 | 0 |
| Doxorubicin | 1 | 0 | 1 |
| DS-6501b | 1 | 1 | 0 |
| EGFR Tyrosine Kinase Inhibitor Therapy | 1 | 1 | 0 |
| Enzalutamide | 1 | 1 | 0 |
| Eribulin | 1 | 1 | 0 |
| Fadraciclib | 1 | 1 | 0 |
| Fasudil | 1 | 1 | 0 |
| Fexagratinib | 1 | 1 | 0 |
| FGFR4 Inhibitor H3B-6527 | 1 | 1 | 0 |
| FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 | 1 | 1 | 0 |
| Firmonertinib | 1 | 1 | 0 |
| Fisogatinib | 1 | 1 | 0 |
| FOLFOX-6 Regimen | 1 | 1 | 0 |
| Foretinib | 1 | 1 | 0 |
| Ganitumab | 1 | 1 | 0 |
| ICX-101 | 1 | 1 | 0 |
| Ipilimumab/Nivolumab Regimen | 1 | 1 | 0 |
| Ivosidenib | 1 | 1 | 0 |
| JQ1 | 1 | 1 | 0 |
| KRAS G12D Inhibitor HRS-4642 | 1 | 1 | 0 |
| Lestaurtinib | 1 | 1 | 0 |
| Leucovorin | 1 | 1 | 0 |
| Lorlatinib | 1 | 0 | 1 |
| Lumretuzumab | 1 | 1 | 0 |
| Mitogen-Activated Protein Kinase Kinase Inhibitor | 1 | 1 | 0 |
| Mitomycin | 1 | 0 | 1 |
| Mobocertinib | 1 | 1 | 0 |
| Nab-paclitaxel | 1 | 0 | 1 |
| Niraparib | 1 | 1 | 0 |
| NSC84167 | 1 | 1 | 0 |
| Onartuzumab | 1 | 1 | 0 |
| Onatasertib | 1 | 1 | 0 |
| Oxaliplatin | 1 | 0 | 1 |
| Paclitaxel Liposome | 1 | 1 | 0 |
| Pan-AKT Kinase Inhibitor GSK690693 | 1 | 1 | 0 |
| Panitumumab | 1 | 0 | 1 |
| Panobinostat | 1 | 1 | 0 |
| Pan-RAF/MEK Molecular Glue NST-628 | 1 | 1 | 0 |
| PD-1 Ligand Inhibitor | 1 | 1 | 0 |
| Pertuzumab/Trastuzumab Regimen | 1 | 0 | 1 |
| PI3K/BET Inhibitor LY294002 | 1 | 1 | 0 |
| Pilaralisib | 1 | 1 | 0 |
| Platinum Compound | 1 | 0 | 1 |
| Pyrotinib | 1 | 1 | 0 |
| Radioactive Iodine | 1 | 1 | 0 |
| Raltitrexed | 1 | 0 | 1 |
| Refametinib | 1 | 1 | 0 |
| Regorafenib | 1 | 1 | 0 |
| Regorafenib Anhydrous | 1 | 1 | 0 |
| Rilotumumab | 1 | 1 | 0 |
| Roflumilast | 1 | 1 | 0 |
| Rucaparib | 1 | 1 | 0 |
| Salirasib | 1 | 1 | 0 |
| Sapanisertib | 1 | 1 | 0 |
| Savolitinib | 1 | 1 | 0 |
| SCH772984 | 1 | 1 | 0 |
| Selpercatinib | 1 | 1 | 0 |
| Setidegrasib | 1 | 1 | 0 |
| Sirolimus | 1 | 1 | 0 |
| Talazoparib | 1 | 1 | 0 |
| Tarloxotinib | 1 | 1 | 0 |
| Taselisib | 1 | 1 | 0 |
| Tgx 221 | 1 | 1 | 0 |
| TGX221 | 1 | 1 | 0 |
| Tislelizumab | 1 | 1 | 0 |
| UO126 | 1 | 1 | 0 |
| Vistusertib | 1 | 1 | 0 |
| Volasertib | 1 | 1 | 0 |
| WRN Inhibitor HRO761 | 1 | 1 | 0 |
| WRN Inhibitor RO7589831 | 1 | 1 | 0 |
| Zenocutuzumab-zbco | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.